Drug Profile
Research programme: designed repeat proteins - Molecular Partners/AbbVie
Alternative Names: AGN-151200; DARPin therapies for eye disorders - Molecular Partners/Allergan; MP 0260; MP0260 (dual anti-vascular endothelial growth factor A [VEGF-A]/anti-platelet derived growth factor B [PDGF-B] DARPin); Multi‐VEGF/PDGF DARPin - Allergan/Molecular PartnersLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Molecular Partners AG
- Developer AbbVie; Molecular Partners AG
- Class Eye disorder therapies; Proteins
- Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Eye disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Age-related-macular-degeneration in Switzerland (Ophthalmic)
- 28 Mar 2022 No recent reports of development identified for research development in Eye-disorders in Switzerland (Ophthalmic)
- 08 May 2020 Allergan has been acquired and merged into AbbVie